MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CNTB had -$2,787K decrease in cash & cash equivalents over the period. -$17,440K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,787K
Free Cash flow
-$17,440K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-17,200 -23,171
Share-based compensation expense
916 1,893
Depreciation and amortization
179 344
Accretion of discounts on available-for-sale investments
169 537
Loss on disposal of property and equipment
0 -34
Accounts receivable, net
17 -789
Prepaid expenses and other assets
1,811 3,524
Other non-current assets
-1 7
Accounts payable
-300 1,952
Accrued liabilities
999 131
Contract liabilities
1 0
Operating lease liabilities
-1 56
Contract assets
-0
Other non-current liabilities
-4 -510
Net cash used in operating activities
-17,406 -22,550
Purchases of short-term investments
0 30,470
Proceeds from maturities and sales of short-term investments
14,380 15,340
Purchases of property and equipment
34 384
Proceeds from sale of property and equipment
0 2
Net cash (used in) provided by investing activities
14,346 -15,512
Proceeds from purchases under the espp
0 143
Proceeds from exercise of stock options
215 20
Net cash provided by financing activities
215 163
Effect of exchange rate changes on cash and cash equivalents
58 299
Net decrease in cash and cash equivalents
-2,787 -37,600
Cash and cash equivalents at beginning of period
78,232 -
Cash and cash equivalents at end of period
37,845 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Connect Biopharma Holdings Ltd (CNTB)

Connect Biopharma Holdings Ltd (CNTB)